Oculogica is proud to announce that Health Canada has approved the EyeBOX concussion diagnostic, an innovative device designed to assist healthcare providers in the diagnosis of concussions. This regulatory approval marks a major milestone for EyeBOX, which will now be available to healthcare professionals throughout Canada to help quickly and accurately assess mild traumatic brain injuries (mTBIs).
EyeBOX is the first and only FDA-cleared concussion diagnostic that does not require a pre-injury baseline test. EyeBOX tracks eye movements through a simple, four-minute test, providing objective data that can assist clinicians in diagnosing a concussion.
“We are thrilled to have received Health Canada approval for EyeBOX,” said Rosina Samadani, CEO of Oculogica. “This approval allows us to offer an innovative, science-backed tool that has the potential to revolutionize how concussions are diagnosed in Canada.”
Health Canada’s approval paves the way for healthcare providers to access this technology and incorporate it into their concussion diagnosis, enhancing patient care, and improving safety for athletes.
Oculogica Inc. is an eye-tracking-based, neuro-diagnostic company founded by Dr. Uzma Samadani, a neurosurgeon at the Minneapolis VA Medical Center. The company has developed the EyeBOX, the first and only FDA-cleared baseline-free aid in the diagnosis of concussion to help physicians objectively categorize concussion. EyeBOX is a 4-minute test for ages 5 to 67. EyeBOX is used by leading healthcare organizations, including Midwest Orthopedics at Rush University and Mayo Clinic. To learn more about the company and EyeBOX, visit www.oculogica.com.